MAYNE PHARMA GROUP LIMITED

ASX:MYXPharmaceuticals, Biotechnology & Life Sciences

81.9M shares on issueASX (delayed) · snapshot 11 Sept 202688.3M fully diluted+7.9% if every option and right converts$3.00price · delayed$245.7Mmarket cap · indicative

Today’s holders own 92.7% of what they think they own, once every option and right converts.

Minimal

Dilution risk

Options/rights overhang 8% of shares

Absolute levels — not a ranking against other companies.

Cash runwayno data — not a quarterly (4C/5B) cash filer

Share-count growth (24m)0.0%no issuance filings since 2024

Raise cadence (24m)0 cash raises

Options & rights overhang7.9% of shares

In-the-money supplyno data — no exercise price on record

Pending proposed issuesnone

MAYNE PHARMA GROUP LIMITED's ordinary share count was 82M as of August 2026. The company has not lodged new share-issuance filings since January 2024 and has had no capital raises in the past 24 months. Options and rights on issue could convert into 6M new shares, representing 7.9% of the current share count, though no expiry date for these securities is on record and none are in the money. The company does not have a current quarterly cash report on record, so no cash balance or funding-runway figure is disclosed on that basis. No proposed securities issues are pending.

AI-generated summary of this page's cited filings · updated 9 Sept 2026

Get told when this changes

Set up alerts

Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.

7.9%

Options & rights overhang

—

In-the-money supply · no stated strikes

Raises · last 12 months

—

Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue

Weekly counts from ASX records. Dots mark cash capital raises. Latest count 81.9M per ASX (delayed) (snapshot 11 Sept 2026).

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

Date	Form	Security	On issue, per this filing	Source
8 Sept 2026	3G · unquoted	MYX : ORDINARY FULLY PAID	81.9M	Appendix 3G
8 Sept 2026	3H · cancellation	MYX : ORDINARY FULLY PAID	81.9M	Appendix 3H
28 Aug 2026	2A · quoted issue	MYX : ORDINARY FULLY PAID	81.9M	Appendix 2A
5 Aug 2026	3G · unquoted	MYX : ORDINARY FULLY PAID	81.2M	Appendix 3G
5 Aug 2026	3H · cancellation	MYX : ORDINARY FULLY PAID	81.2M	Appendix 3H

Free account

40 filings on record — Full issuance history

Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Capital raises

No equity raises in the last 24 months.

Free account

Full raise history

Issue price, shares issued, brokers and stated purpose for every raise on record.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account

Forward supply calendar

Option expiries and proposed issues on one forward timeline, with the securities each could add.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

About 99% of the 15% placement capacity left — about 1% used by Appendix 3B filings in the last 12 months (estimate, as at 2026-09-12). Holder-approved issues and any later ratification are not deducted, so the true headroom can be higher.

Free account

Placement capacity — LR 7.1 / 7.1A

The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

7.9%

Options & rights overhang · of current shares

—

In-the-money supply · no stated strikes

6.5M

Potential new shares

—

Nearest expiry

What this supply is, and what converts it

Condition-triggered6.4M · 7.8% of shares
Performance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Converts on terms28k · 0.0% of shares
Convertibles with no exercise price — they convert on their own terms, so they are shares in all but name.

Exercise price on record: 0 priced, 6.5M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.

Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.

What a price move would switch on

No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 6.5M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.

Code	Security	Type	Exercise price	Expiry	On issue	Source
MYXAA	Notes	Converts on terms	—	—	28k	Filing
MYXAN	Performance rights	Condition-triggered	—	—	6.4M	Filing Meeting

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.

1 class ceased in the last 12 months and is not counted above

The company’s own Appendix 2A restates each of these at zero. They are excluded from the overhang, the in-the-money supply and every figure on this page. Each count is the filing’s own count of securities in the class, not a share count — a 2A never states what one security converts into.